美女免费一级视频在线观看
As many biotech and pharmaceutical organizations reorient their corporate identities to be more science-focused, it doesn’t hurt to have a moniker like Spectrum Science.
According to CEO Jonathan Wilson, 2023 marked a turning point in terms of agency/client engagement in the almost-post-COVID-19 world. If biotech clients conserved cash during the fiscal doldrums of 2022, he notes, they started investing again last year — with more to come in the remaining months of 2024.
That’s where Spectrum Science inserts itself into the process: Since its inception, the company has strived to help client organizations find their voice and share stories around their investments. Building this scientific narrative, in turn, informs that organization’s marketing efforts, especially when it is investing heavily in research and development.
“Companies come to us and say, ‘I’m doing R&D, but I don’t have a story out in the marketplace about my commitment to a certain patient population. Can you help me frame that story? Because once I do that, then I can promote, activate and engage,’” Wilson explains. “We do a lot of things, but our R&D comms is something pretty special.”
While Wilson reports that Spectrum Science didn’t meet its own lofty expectations during 2023, revenue still grew more than 6%, to $80 million from $75.2 million in 2022. Head count fell from 303 full-timers at the year’s outset to 275 at its conclusion.

The revenue growth came on the heels of new assignments from AstraZeneca, Zoetis, UCB, Harmony Biosciences and Odyssey Therapeutics. However, when asked to identify some highlights on the client front, Wilson points to one of the agency’s highest-profile assignments: A social-media push for Moderna. He believes the agency’s use of TikTok and Instagram Reels not only educated audiences about the risks of cytomegalovirus (CMV), but also helped directly enroll participants into a Phase III trial for an investigational vaccine.
“Through cost-efficient channels, we maximized our impact, ensuring progress in the fight against birth defects caused by CMV,” he adds.
Spectrum Science also remained active on the acquisition front. Backed by PE firm Knox Lane, the company ended 2023 with a bang by snapping up well-regarded independent shop CrowdPharm as well as its partner consultancy Hot Iron Health.
In the deal’s wake, CrowdPharm founder and president Mike Myers leads the advertising and consulting pillar of the combined company as president, advertising. Spectrum Science also added Eversana alum Amy Hutnik as chief commercial officer.
Now that drugmakers have navigated what Wilson calls the “great reset” of 2023, he believes they are once again ready to invest more aggressively in marketing programs.
“Our clients are tasked with making sure that, at every opportunity, they have the most expert, impactful and highest value partnership that they can find,” he says. “It’s great for them to raise the bar on what they’re looking for in a partnership.”
. . .
Work we wish we did
Smart marketing initiatives that seek to destigmatize historically taboo conversations can be incredible gateways to healthy dialogue. I admire the work that Astellas has done with Veozah to introduce a more authentic conversation about menopause into the mainstream, notably the move to advertise during the Super Bowl. That boldness, paired with the Biden administration’s executive order to expand research on women’s health, redefines and advances our perception of what truly comprehensive wellness can look like. — Amy Hutnik